By FieldPulse Editorial · March 25, 2026
Tags: FDA, Oncology, Clinical Trials
The FDA approved Corcept Therapeutics' Lifyorli for platinum-resistant ovarian cancer, clearing it four months ahead of its target date. The approval marks a significant turnaround for a drug that previously faced an FDA rejection.
Corcept Therapeutics scored a landmark FDA approval on March 25 for Lifyorli (relacorilant) in platinum-resistant ovarian cancer — and the circumstances surrounding the clearance make it one of the more compelling regulatory stories of the year. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA), a novel mechanism that sets it apart from the established landscape of ovarian cancer treatments. The drug is approved in combination with nab-paclitaxel, a chemotherapy agent already widely used in this patient population. The approval rests on data from the ROSELL